Akebia Therapeutics, Inc. Income Statement
AKBA|10 years of annual SEC 10-K data (FY2014-FY2025)
Line items include revenue, cost of goods sold, gross profit, operating expenses, interest, taxes, and net income with per-share data across 10 fiscal years. All figures from audited SEC 10-K filings.
Akebia Therapeutics, Inc. reported $236M in revenue and $5M in net loss for FY2025. Revenue has grown at a 105.3% compound annual rate over the past 7 years.
Based on SEC 10-K filings.
Key Data Points
- Altman Z-Score -2.76 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
| Item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2015 | FY2014 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $236.2M | $160.2M | $194.6M | $292.5M | $335.0M | $207.7M | $181.2M | $1.5M | $0 | $0 |
| Cost of Revenue | $39.5M | $63.2M | $74.1M | $85.6M | $145.3M | $7.8M | $6.3M | $6.3M | - | - |
| SG&A Expense | $107.5M | $106.5M | $100.2M | $138.6M | $149.5M | $87.1M | $27.0M | $22.2M | $7.0M | $2.9M |
| R&D Expense | $62.4M | $37.7M | $63.1M | $130.0M | $323.0M | $291.0M | $230.9M | $115.8M | $8.9M | $5.6M |
| Operating Income | $23.5M | -$50.5M | -$46.3M | -$80.8M | -$286.3M | -$178.2M | -$76.7M | -$136.5M | -$15.9M | -$8.5M |
| Interest Expense | - | - | - | - | - | - | - | - | -$704.0K | -$1.6M |
| Income Tax | $1.6M | $0 | $0 | $0 | -$6.6M | -$28.3M | -$28.3M | -$28.3M | - | - |
| Net Income | -$5.3M | -$69.4M | -$51.9M | -$94.2M | -$279.7M | -$143.6M | -$73.7M | -$135.7M | -$13.2M | -$8.2M |
| EPS (Basic) | -$0.28 | -$0.28 | -$0.52 | -$2.77 | -$2.36 | - | - | - | - | - |
| EPS (Diluted) | -$0.28 | -$0.28 | -$0.52 | -$2.77 | -$2.36 | -$2.47 | -$1.69 | -$3.60 | -$126.94 | -$27.82 |
| Shares Outstanding | 224.8M | 194.6M | 184.1M | 177.0M | 148.1M | 121.7M | 116.9M | 47.6M | 20.4M | 1.4M |
| Operating Margin | 10.0% | -31.5% | -23.8% | -27.6% | -85.5% | -85.8% | -42.3% | -8889.9% | - | - |
| Profit Margin | -2.3% | -43.3% | -26.7% | -32.2% | -83.5% | -69.1% | -40.6% | -8843.5% | - | - |